OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
BioSpace - 16 May 2025OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update ...
phase 2b
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update ...
Vaxart Publishes Positive, Complete Data from a Phase 2b
GlobeNewswire - 14 May 2025Vaxart Publishes Positive, Complete Data from a Phase 2b ...
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Business Wire - 14 May 2025The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 ...
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
Yahoo Finance - 15 May 2025Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial ...
Breakthrough: New Cancer Drug Shows Survival Benefits in Advanced Pancreatic Cancer Trial Results
Stock Titan - 14 May 2025Breakthrough: New Cancer Drug Shows Survival Benefits in Advanced Pancreatic Cancer Trial Results ...
EMA approves Moleculin’s application for Phase IIb/III AML trial
Clinical Trials Arena - 13 May 2025EMA approves Moleculin’s application for Phase IIb/III AML trial ...
Rein Therapeutics initiates renew phase 2 trial for IPF treatment
PharmaTimes - 13 May 2025Rein Therapeutics initiates renew phase 2 trial for IPF treatment ...
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
GlobeNewswire - 15 May 2025Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris ...
Revolutionary Oral Pill Vaccine Reduces Norovirus Infection by 30% in Landmark Phase 2b Trial
Stock Titan - 14 May 2025Revolutionary Oral Pill Vaccine Reduces Norovirus Infection by 30% in Landmark Phase 2b Trial ...
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
Business Wire - 14 May 2025Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights ...
LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy
Clinical Trials Arena - 12 May 2025LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy ...
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Yahoo Finance - 13 May 2025Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates ...
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
GlobeNewswire - 15 May 2025BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates ...
GH Research's New Depression Drug Achieves 100% Remission in Postpartum Trial, Impresses in Phase 2b Studies
Stock Titan - 15 May 2025GH Research's New Depression Drug Achieves 100% Remission in Postpartum Trial, Impresses in Phase 2b Studies ...
KALA's PCED Drug Could Reach 100,000 Patients - Q3 Trial Results Coming
Stock Titan - 14 May 2025KALA's PCED Drug Could Reach 100,000 Patients - Q3 Trial Results Coming ...
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire - 12 May 2025CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates ...
Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial
Stock Titan - 13 May 2025Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial ...
Akero Therapeutics and HistoIndex Present New Analyses of
GlobeNewswire - 10 May 2025Akero Therapeutics and HistoIndex Present New Analyses of ...
BiomX Breakthrough: Phase 2 Trial Reveals 40% Superior Efficacy in Fighting Antibiotic-Resistant Infections
Stock Titan - 15 May 2025BiomX Breakthrough: Phase 2 Trial Reveals 40% Superior Efficacy in Fighting Antibiotic-Resistant Infections ...